Hostname: page-component-cc8bf7c57-77pjf Total loading time: 0 Render date: 2024-12-10T01:44:41.581Z Has data issue: false hasContentIssue false
  • English
  • Français

In the Business of Dying: Questioning the Commercialization of Hospice

Published online by Cambridge University Press:  01 January 2021

Joshua E. Perry  and
Robert C. Stone
Get access Rights & Permissions [Opens in a new window]

Extract

In our society, some aspects of life are off-limits to commerce. We prohibit the selling of children and the buying of wives, juries, and kidneys. Tainted blood is an inevitable consequence of paying blood donors; even sophisticated laboratory tests cannot supplant the gift-giving relationship as a safeguard of the purity of blood. Like blood, health care is too precious, intimate, and corruptible to entrust to the market.

The hospice movement in the United States is approximately 40 years old. During these past four decades, the concept of holistic, multidisciplinary care for patients (and their families) who are suffering from a terminal illness has evolved from a modest, grassroots constellation of primarily volunteer-run and community-governed endeavors to a multimillion dollar industry where the surviving nonprofits compete with for-profit providers, often publicly traded, managed by M.B.A.-trained executives, and governed by corporate boards. The relatively recent emergence of for-profit hospice reflects an increasing commercialization of health care in the United States, the potentially adverse impact of which has been well documented.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 39 , Issue 2 , Summer 2011 , pp. 224 - 234
Copyright
Copyright © American Society of Law, Medicine and Ethics 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Woolhandler, S. and Himmelstein, D. U., “When Money Is the Mission – The High Costs of Investor-Owned Care,” New England Journal of Medicine 341, no. 6 (1999): 444–446, at 446. Making a similarly impassioned argument five years later, Woolhandler and Himmelstein highlighted concerns that are particularly salient in the context of hospice: “Investor-owned care embodies a new value system that severs the community roots and Samaritan traditions of hospitals, makes physicians and nurses into instruments of investors, and views patients as commodities.” Woolhandler, S. and Himmelstein, D. U., “The High Costs of For-Profit Care,” Canadian Medical Association Journal 170, no. 12 (2004): 1814–1815.CrossRefGoogle Scholar
See Relman, A. S., “Medical Professionalism in a Commercialized Health Care Market,” JAMA 298, no. 22 (2007): 2668–2670; Jonsen, A. R., “A Note on the Notion of Commercialism,” Cambridge Quarterly Healthcare Ethics 16, no. 4 (2007): 368–373, at 369 (“In our culture, medicine has, for the most part, been a commercial activity [except when monks were its practitioners] and has, as such, always presented moral problems.”); Fins, J. J., “Commercialism in the Clinic: Finding Balance in Medical Professionalism,” Cambridge Quarterly Healthcare Ethics 16, no. 4 (2007): 425–432, at 425 (“There is a palpable malaise in American medicine as clinical practice veers off its moorings, swept along by a new commercialism that is displacing medical professionalism and its attendant moral obligations.”); Andereck, W. S., “Commodified Care,” Cambridge Quarterly Healthcare Ethics 16, no. 4 (2007): 398–406 (examining the characteristics of healthcare commodification in the context of medical care and exploring its effects on the doctor-patient relationship); Churchill, L. R., “The Hegemony of Money: Commercialism and Professionalism in American Medicine,” Cambridge Quarterly Healthcare Ethics 16, no. 4 (2007): 407 (exploring the cultural meaning attached to money and its pervasive force throughout medical research, education, and the delivery of health services); Rodwin, M. A., “Medical Commerce, Physician Entrepreneurialism, and Conflicts of Interest,” Cambridge Quarterly Healthcare Ethics 16, no. 4 (2007): 387–397 (tracing the historical development of medical commerce in the United States from the late 18th century through the early 21st century, and arguing that the primary problem of commercialism in medicine today is the conflict of interest that arises when loyalty to patients and the exercise of independent professional judgment is compromised by physician entrepreneurship); Needleman, J., “A Philosopher's Reflection on Commercialism in Medicine,” Cambridge Quarterly Healthcare Ethics 16, no. 4 (2007): 433–438, at 437 (2007) (advocating for reflection among physicians as to “how…the money factor…impact[s] the human values often assumed to define the art of medicine, understood as the work of always and in everything giving first priority to the health and well-being of the individual patient[.]”); McArthur, J. H. and Moore, F. D., “The Two Cultures and the Health Care Revolution,” JAMA 277, no. 12 (1997): 985–989 (arguing that while traditions of commercialism and professionalism both share a central role in the evolution of social institutions in the United States, “threats” exist to the “quality and scope of medical care” when “the tradition of medical professionalism is overtaken by the commercial ethic and by corporations seeking profit for investors from clinical care of the sick.”).10.1001/jama.298.22.2668CrossRefGoogle Scholar
Id. (McArthur, and Moore, ), at 986. See also Byock, I. R., “Ethics from a Hospice Perspective,” American Journal of Hospice & Palliative Care 11, no. 4 (1994): 9–11, at 9 (“Ethical considerations are central to hospice practice. Unlike many areas of medicine in which it is the occasional case that presents an apparent ethical dilemma, care at the end of life is full of ethically poignant and emotionally charged situations.” The potentially crippling impact of illness upon patients seeking information and making decisions about their health care is comprehensively summarized by Hall, M. A. and Schneider, C. E. in “Patients as Consumers: Courts, Contracts, and the New Medical Marketplace,” Michigan Law Review 106, no. 4 (2008): 643–689 (“Illness disables…pains…exhausts…erodes control…enforces dependence…disorients…baffles…terrifies…[and] isolates.”).Google Scholar
See Relman, , supra note 2, at 2668.Google Scholar
See Rodwin, , supra note 2, at 387–395.Google Scholar
See generally Herzlinger, R., Who Killed Health Care? (New York: McGraw-Hill, 2007): at 211.Google Scholar
Eighty-five percent of all hospice care is paid by the government, either through Medicare or Medicaid reimbursements. Cetti, J., “Measure the Social Outcomes of Nonprofits,” Journal of Palliative Medicine 12, no. 1 (2009): 12–13. As of 2008, the Medicare benefit cost the government $11.4 billion. National Association for Home Care and Hospice, Hospice Facts and Statistics, September 2009, available at <www.nahc.org/facts/hospicestats09.pdf> (last visited February 25, 2011).CrossRefGoogle Scholar
See generally Cerminara, K. L., “Pandora's Dismay: Eliminating Coverage-Related Barriers to Hospice Care,” Florida Coastal Law Review 11, no. 2 (2010): 107–154, at 153 (“Hospice care costs less than curative care …”); Ash, M. and Arons, S., “Economic Parameters of End-of-Life Care: Some Policy Implications in an Era of Health Care Reform,” Western New England Law Review 31, no. 2 (2009): 305–332, at 315–320 (summarizing the literature); Taylor, D. H. Jr. et al., “What Length of Hospice Use Maximizes Reduction in Medical Expenditures Near Death in the US Medicare Program?” Social Science & Medicine 65, no. 7 (2007): 1466–1478, at 1474 (finding no cost differences between hospice users and controls when looking at the entire last year of life, but finding clear evidence of savings for Medicare attributable to hospice during the period of time in the last year of life that hospice is actually used in the Medicare program); Campbell, D. E. et al., “Medicare Program Expenditures Associated with Hospice Use,” Annals of Internal Medicine 140, no. 4 (2004): 269–277, at 275 (finding that hospice is cost-neutral to cost-saving for persons who die of cancer, but generally adds cost for those who do not die of cancer); Harrison, J. P. and Ford, D., “A Comprehensive Community-Based Model for Hospice Care,” American Journal of Hospice & Palliative Medicine 24, no. 2 (2007): 119–125 (“appropriate use of hospice could generate savings of 46.5% during the last month of life, 17% during the last 6 months of life, and 10.4% during the last year of life”); Buntin, M. B. and Huskamp, H., “What Is Known about the Economics of End-of-Life Care for Medicare Beneficiaries,” Gerontologist 42, no. 3 (2002): 40–48 (summarizing the literature).Google Scholar
McCue, M. J. and Thompson, J. M., “Operational and Financial Performance of Publicly Traded Hospice Companies,” Journal of Palliative Medicine 8, no. 6 (2005): 1196–1206.CrossRefGoogle Scholar
See infra Part III.Google Scholar
See McCue, and Thompson, , supra note 9.Google Scholar
Lorenz, K. A. et al., “The Evidence for Improving Palliative and End of Life Care: A Systematic Review,” Annals of Internal Medicine 148, no. 2 (2008): 147–159; Teno, J. M. et al., “Family Perspectives on End-of-Life Care at the Last Place of Care,” JAMA 291, no. 1 (2004): 88–93; Brumley, R. D., Enguidanos, S. and Cherin, D. A., “Effectiveness of a Home-Based Palliative Care Program for End-of-Life,” Journal of Palliative Medicine 6, no. 5 (2003): 715–724; Greer, D. S. and Mor, V., “An Alternative in Terminal Care: Results of the National Hospice Study,” Journal of Chronic Diseases 39, no. 1 (1986): 9–26.10.7326/0003-4819-148-2-200801150-00010CrossRefGoogle Scholar
Cotter, L. T., “Continuing the Spiritual Transformation of the Hospice Movement,” American Journal of Hospice and Palliative Medicine 24, no. 4 (2007): 257–258.10.1177/1049909107300218CrossRefGoogle Scholar
Relman, A. S., “The New Medical-Industrial Complex,” New England Journal of Medicine 303, no. 17 (1980): 963–970, at 963.10.1056/NEJM198010233031703CrossRefGoogle Scholar
Although the hospice movement was gaining considerable traction by 1980, the concept of for-profit entities offering hospice services was not yet on the radar. This would begin to change in 1983 with the passage of the Tax Equity and Fiscal Responsibility Act of 1982. See infra notes 28–47 and accompanying text.Google Scholar
See Relman, , supra note 14, at 965.Google Scholar
Id.Google Scholar
Id. Although not as rapidly, the for-profit hospice industry would likewise experience dramatic growth during the decades following Congress's decision to create a Medicare hospice benefit. See infra notes 43–47 and accompanying text.Google Scholar
Devereaux, P. J. et al., “Comparison of Mortality Between Private For-Profit and Private Not-For-Profit Hemodialysis Centers: A Systematic Review and Meta-Analysis,” JAMA 288, no. 19 (2002): 2449–2457.10.1001/jama.288.19.2449CrossRefGoogle Scholar
Thamer, M. et al., “Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis,” JAMA 297, no. 15 (2007): 1667–1674.CrossRefGoogle Scholar
Gray, B. H., “An Introduction to the New Health Care for Profit,” in Gray, B. H., ed., The New Health Care for Profit (Washington, D. C.: National Academy Press, 1983): at 8.Google Scholar
Hasan, M. M., “Let's End the Nonprofit Charade,” New England Journal of Medicine 334, no. 16 (1996): 1055–1057.10.1056/NEJM199604183341610CrossRefGoogle Scholar
Kinney, E. D., “For profit Enterprise in Health Care: Can It Contribute to Health Reform?” American Journal of Law & Medicine 36, nos. 2 & 3 (2010): 405–435, at 428–29.10.1177/009885881003600207CrossRefGoogle Scholar
Blumstein, J. F., “The Fraud and Abuse Statute in an Evolving Health Care Marketplace: Life in the Health Care Speakeasy,” American Journal Law & Medicine 22, no. 2–3 (1996): 205–231, at 207. Professor Blumstein cites numerous studies confirming the overutilization that results from perverse economic incentives. See, generally, Office of the Inspector Gen., Dept. of Health & Human Serv., Financial Arrangements Between Physicians and Health Care Businesses, Medicare & Medicaid Guide ¶ 37,838, at 19,933 (May 1989) (“The Medicare patients of referring physicians who owned clinical laboratories received forty-five percent more clinical laboratory services than all Medicare patients in general.”); General Accounting Office, Referrals to Physician-Owned Imaging Facilities Warrant HCFA's Scrutiny, GAO/HHS-95-2, at 10 (1994); and Hillman, B. J. et al., “Frequency and Costs of Diagnostic Imaging in Office Practice - A Comparison of Self-Referring and Radiologist-Referring Physicians,” New England Journal of Medicine 323, no. 23 (1990): 1604–1608, at 1604 (“Studies of the use of diagnostic imaging equipment done in 1990 and 1994 showed that patients of physicians who had an ownership interest in such equipment utilized some equipment 400% more than the patients of nonowning physicians.”); Mitchell, J. M. and Scott, E., “Physician Ownership of Physical Therapy Services: Effects on Charges, Utilization, Profits, and Service Characteristics,” JAMA 268, no. 15 (1992): 2055–2059, at 2057 (“Physicians having ownership interests in physical therapy clinics or radiation therapy centers similarly recommended patient visits to such facilities fifty percent more than did other physicians.”) Additionally, Rodwin's, Marc book, Medicine, Money, and Morals: Physicians’ Conflicts of Interests (1993) includes copious evidence of ways in which physician self-interest results in Medicare abuse. For example, see Rodwin at 97 (citing a December 17, 1987, personal letter from Jim Codo, a medical laboratory salesperson who claimed that “where a high percent of Medicare recipients reside, there is a correspondingly high percent of physicians invested in laboratory ownership arrangements. The government in allowing such [practices]…might as well issue the physician owners their own money press. The physician controls the demand for services, owns the supply of the services, and is guaranteed payment for services by the government.”) and 215 (citing to 18 published studies by academic researchers and government regulators between 1970 and 1992 as evidence “that physicians who make referrals to medical facilities that they either own or have a financial interest in recommend more (or more expensive) medical tests and procedures than do physicians without a financial interest.”).CrossRefGoogle Scholar
Eichenwald, K., “HCA Is Said to Reach Deal on Settlement of Fraud Case,” New York Times, December 18, 2002, at A1 (reporting on an agreement with the Justice Department to pay more than $880 million to settle a long-running inquiry into accusations of health care fraud). See also Wood, E. T., “Feds Win $19.4M in Lawsuit over Renal Care Group Medicare Practices,” NashvillePost.com website, March 23, 2010, available at <http://www.nashvillepost.com/news/2010/3/23/feds_win_194_million_in_lawsuit_over_renal_care_group_medicare_practices> (last visited February 25, 2011). The most egregious example of for-profit fraud specifically in the hospice industry would be that involving SouthernCare Hospice Press Release, Frohsin & Barger, LLC, Alabama Hospice Provider Settles Whistleblower Lawsuit for $24.7 Million, January 16, 2009) (on file with authors). As for fraud in the nonprofit sector, the False Claims Act Legal Center lists St. Barnabas Healthcare and its chain of eight nonprofit hospitals in New Jersey, as 23rd on its list of top False Claim Act fraud feasors since 1986. See <http://www.taf.org/top20/htm> (last visited January 20, 2011). For a specific hospice example, see also Frantz, D., “Hospice Boom Is Giving Rise to New Fraud,” New York Times, May 10, 1998, at A1 (reporting on an indictment of Kirschenbaum, Joseph A. and His “not-for-profit” hospice Samaritan Care that allegedly defrauded Medicare out of $28.5 million).+(last+visited+February+25,+2011).+The+most+egregious+example+of+for-profit+fraud+specifically+in+the+hospice+industry+would+be+that+involving+SouthernCare+Hospice+Press+Release,+Frohsin+&+Barger,+LLC,+Alabama+Hospice+Provider+Settles+Whistleblower+Lawsuit+for+$24.7+Million,+January+16,+2009)+(on+file+with+authors).+As+for+fraud+in+the+nonprofit+sector,+the+False+Claims+Act+Legal+Center+lists+St.+Barnabas+Healthcare+and+its+chain+of+eight+nonprofit+hospitals+in+New+Jersey,+as+23rd+on+its+list+of+top+False+Claim+Act+fraud+feasors+since+1986.+See++(last+visited+January+20,+2011).+For+a+specific+hospice+example,+see+also+Frantz,+D.,+“Hospice+Boom+Is+Giving+Rise+to+New+Fraud,”+New+York+Times,+May+10,+1998,+at+A1+(reporting+on+an+indictment+of+Kirschenbaum,+Joseph+A.+and+His+“not-for-profit”+hospice+Samaritan+Care+that+allegedly+defrauded+Medicare+out+of+$28.5+million).>Google Scholar
See generally, Perry, J. E., “An Obituary for Physician-Owned, Specialty Hospitals,” Health Lawyer 23, no. 2 (December 2010): 24–34.Google Scholar
Carlson, M. D. A., Gallo, W. T., and Bradley, E. H., “Ownership Status and Patterns of Care in Hospice: Results from the National Home and Hospice Care Survey,” Medical Care 42, no. 5 (2004): 432–438, at 432 (citing Aaronson, W. E., Zinn, J. S., and Rosko, M. D., “Do For-Profit and Not-For-Profit Nursing Homes Behave Differently?” Gerontologist 34, no. 6 (1994): 775–786; Harrington, C. et al., “Does Investor Ownership of Nursing Homes Compromise the Quality of Care?” American Journal of Public Health 91, no. 9 (2001): 1452–1455; Bradley, E. H. and Walker, C. W., “Education and Advance Care Planning in Nursing Homes: The Impact of Ownership Type,” Nonprofit and Voluntary Sector Quarterly 27, no. 3 (1998): 339–357; Weisbrod, B. A. and Schlesinger, M., “Public, Private, Nonprofit Ownership and the Response to Asymmetric Information: The Case of the Nursing Homes,” in Rose-Ackerman, S., ed., The Economics of Nonprofit Institutions (New York: Oxford American Press, 1986); Chou, S. Y., “Asymmetric Information, Ownership and Quality of Care: An Empirical Analysis of Nursing Homes,” Journal of Health Economics 21, no. 2 (2002): 293–311. See generally Comondore, V. R. et al., “Quality of Care in For-Profit and Not-For-Profit Nursing Homes: Systematic Review and Meta-Analysis,” BMJ 339, no. 7717 (2009): 381–384.10.1097/01.mlr.0000124246.86156.54CrossRefGoogle Scholar
See Enck, R. E., “Hospice - Palliative Medicine: A Look Back and Into the Future,” American Journal of Hospice and Palliative Medicine 26, no. 6 (2009): 429–431.10.1177/1049909109352225CrossRefGoogle Scholar
Kubler-Ross, E., On Death and Dying (New York: Scribner Classics, 1997): at 31.Google Scholar
Greer, D. S., “Hospice: From Social Movement to the Health Care Industry,” Transactions of the American Clinical and Climatological Association 97 (1986): 82–87.Google Scholar
Rasmussen v. Fleming, 741 P.2d 674, 678 (Ariz 1987).Google Scholar
See Greer, , supra note 30, at 83.Google Scholar
See Enck, , supra note 28, at 429.Google Scholar
Tax Equity and Fiscal Responsibility Act of 1982, Pub. L. No. 97–248, § 122, 96 Stat. 324 (1982).Google Scholar
42 C.F.R. § 418.22(b) (2009).Google Scholar
42 C.F.R. § 418.302 (2009).Google Scholar
42 C.F.R. § 418.64-.106 (2009).CrossRefGoogle Scholar
Greer, D. S. and Mor, V., “How Medicare Is Altering the Hospice Movement,” Hastings Center Report 15, no. 5 (1985): 5–9, at 5–6.10.2307/3563198CrossRefGoogle Scholar
Id.Google Scholar
Id. and Relman, , supra note 14.Google Scholar
See Greer, and Mor, , supra note 38.Google Scholar
Iglehart, J. K., “A New Era of For-Profit Hospice Care - The Medicare Benefit,” New England Journal of Medicine 360, no. 26 (2009): 2701–2703, at 2701.CrossRefGoogle Scholar
Medicare Payment Advisory Commission, Rep. to the Congress on Medicare Payment Policy, March 2009. But see supra note 8.Google Scholar
U.S. Gov’t Accountability Office, GAO-05-42, Medicare Hospice Care: Modifications to Payment Methodology May Be Warranted 1 (October 2004).Google Scholar
MedPAC, “Report to Congress: Medicare Payment Policy,” Hospice, March 2010, at 141; MedPAC, “Report to Congress: Reforming the Delivery System, Evaluating Medicare's Hospice Benefit,” June 2008, at 216.Google Scholar
Id. (MedPAC 2010), at 147. Approximately 1600 for-profit hospice programs currently operate in the United States compared to 1200 not-for-profit hospice organizations. von Gunten, C. F., “Profit or Not-For-Profit: Who Cares?” Journal of Palliative Medicine 11, no. 7 (2008): 954.CrossRefGoogle Scholar
See MedPAC (2010), supra note 45, at 147.Google Scholar
Koehn, D., “The Business of Hospice Gets Corporate Attention,” Tampa Tribune, January 18, 2004, at 1. Such practices are reminiscent of pharmaceutical industry tactics. See infra note 51.Google Scholar
See also Frantz, D., “Hospice Boom Is Giving Rise to New Fraud,” New York Times, May 10, 1998, at A1.Google Scholar
Moos, B., “Business of Dying Undergoes Change: For-Profit Firms Enter Small Agencies' Turf as Hospice Care Grows,” Dallas Morning News, May 22, 2005, at 1D.Google Scholar
Prior evidence of a variety of unsavory marketing tactics employed by pharmaceutical company representatives provides a cautionary tale, well documented by Dr.Angel, Marcia, former editor of the New England Journal of Medicine, in her 2004 book The Truth about the Drug Companies. The hard sell, questionably accurate information, and gift incentives can go a long way toward building market share, but not necessarily toward empowering a potential patient to make a decision that is in her best interest and consistent with the hospice philosophy.Google Scholar
See MedPAC (2010), supra note 45, at 144 and 147. The report notes that financial incentives “may have led to inappropriate utilization of the benefit among some hospices.”Google Scholar
Landis v. Hospice Care of Kansas, 2010 U.S. Dist. LEXIS 129484, *6 (Kan, D. Dec. 7, 2010) (alleging business practices at Hospice Care of Kansas that included “setting aggressive census targets for each HCK branch Office; staff incentives and monetary bonuses for meeting the aggressive census targets; threatening staff with terminations or reductions in hours if the census fell below targets; instructing staff to inaccurately document the condition of patients to make them appear appropriate for hospice and to avoid detection …; implementing procedures that delayed the discharge or made it difficult to discharge ineligible patients; challenging or ignoring staff and physician recommendations to discharge patients; and disregarding or ignoring compliance concerns raised by an outside consultant” and resulted in “admission, retention, and submission of claims to Medicare for patients that were ineligible for the hospice benefit.”Google Scholar
See Iglehart, , supra note 42, at 2702 (citing to Medicare Payment Advisory Commission, Rep. to the Congress on Medicare payment policy [March 2009]); Wachterman, M. W. et al., “Association of Hospice Agency profit Status With Patient Diagnosis, Location of Care, and Length of Stay,” JAMA 305, no. 5 (2011): 472–479 (citing Huskamp, H. A. et al., “Providing Care at the End of Life: Do Medicare Rules Impede Good Care?” Health Affairs 20, no. 3 (2001): 204–211).Google Scholar
Kaiser Health News, “MedPAC Approves Recommendation to Revise Medicare Reimbursement System for Hospice Care Providers,” January 12, 2009, available at <http://www.kaiserhealthnews.org/daily-reports/2009/january/12/dr00056387> (last visited February 25, 2011).+(last+visited+February+25,+2011).>Google Scholar
Lindrooth, R. C. and Weisbrod, B. A., “Do Religious Nonprofit and For-Profit Organizations Respond Differently to Financial Incentives? The Hospice Industry,” Journal of Health Economics 26, no. 2 (2007): 342–357, at 344.CrossRefGoogle Scholar
Huskamp, H. A. et al., “Variation in Patients' Hospice Costs,” Inquiry 45, no. 2 (2008): 232–244, at 241 (“Our results suggest that average per day costs were markedly higher for stays of one or two days than for longer stays, and that total costs for longer stays increased at a decreasing rate as the length of stay increased.”)CrossRefGoogle Scholar
See Wachterman, , supra note 54, at 477–78; Lorenz, K. A. et al., “Cash and Compassion: Profit Status and the Delivery of Hospice Services,” Journal of Palliative Medicine 5, no. 4 (2002): 507–514.Google Scholar
See Lindrooth, and Weisbrod, , supra note 56, at 345; see also Wachterman, , supra note 54, at 472 (citing Gruneir, A. et al., “Hospice Care in the Nursing Home: Changes in Visit Volume from Enrollment to Discharge among Longer-Stay Residents,” Journal of Pain Symptom Management 32, no. 5 (2006): 478–487; Carney, K. et al., “Hospice Costs and Medicare Reimbursement: An Application of Break-Even Analysis,” Nursing Economics 7, no. 1 (1989): 41–48; Nicosia, N. et al., “The Medicare Hospice Payment System: A Consideration of Potential Refinements,” Health Care Financing Review 30, no. 4 (2009): 47–59; Cheung, L. et al., The Costs of Hospice Care: An Actuarial Evaluation of the Medicare Hospice Benefit (New York: Milliman USA, 2003).Google Scholar
See MedPAC (2010), supra note 45, at 146.Google Scholar
Id. (summarizing the March 2009 Commission recommendations).Google Scholar
See Wachterman, et al., supra note 54, at 478 (finding that hospice agencies, depending on profit status, do differentially enroll patients with dementia and other noncancer diagnoses, resulting in patterns of patient selection that leave “nonprofit hospice agencies disproportionately caring for the most costly patients - those with cancer and those tending to begin hospice very late in their course of illness; as a result, those hospices serving the neediest patients may face difficult financial obstacles to providing appropriate care in this fixed per-diem payment system.”)Google Scholar
See Lindrooth, and Weisbrod, , supra note 56, at 351–355. See MedPAC (2010), supra note 45, at 151 (“[P]roviders that exceeded the hospice cap, appeared to have a higher prevalence of long-stay patients across all diagnoses, suggesting some patient selection may be at work.”).Google Scholar
See Lorenz, et al., supra note 58, at 511.Google Scholar
Accord Wachterman, , supra note 54, at 478 (“For-profit hospices had significantly more patients with stays exceeding 365 days and fewer patients with stays less than 7 days.”). See Ohri, generally S., Essays in Health Economics (2007) (unpublished Ph.D. dissertation, Univ. of CA, Irvine) (on file with authors).Google Scholar
Taylor, D. H. Jr. et al., “What Length of Hospice Use Maximizes Reduction in Medical Expenditures Near Death in the U.S. Medicare Program,” Social Science & Medicine 65, no. 7 (2007): 1466–1476, at 1470. See also Cerminara, K. L., “Hospice and Health Care Reform: Improving Care at the End of Life” (unpublished manuscript on file with authors at 32–33) (summarizing literature justifying longer patient stays).CrossRefGoogle Scholar
Kinzbrunner, B. M., “For Profit vs. Not-for-Profit Hospice: It Is the Quality That Counts,” Journal of Palliative Medicine 5, no. 4 (2002): 483–485, at 484.10.1089/109662102760269715CrossRefGoogle Scholar
42 U.S.C. Sec. 1395x (dd) (2) (B).Google Scholar
42 U.S.C. Sec. 1395x (dd) (1) (A) - (H); Code of Federal Regulations 418.64.Google Scholar
Code of Federal Regulations 418.70 – 418.78.Google Scholar
Carlson, M. D. A., Gallo, W. T., and Bradley, E. H., “Ownership Status and Patterns of Care in Hospice: Results from the National Home and Hospice Care Survey,” Medical Care 42, no. 5 (2004): 432–438.CrossRefGoogle Scholar
See Lorenz, et al., supra note 58, at 511–512. See also O'Neill, S. M., Ettner, S. L., and Lorenz, K. A., “Paying the Price at the End of Life: A Consideration of Factors That Affect the Profitability of Hospice,” Journal of Palliative Medicine 11, no. 7 (2008): 1002–1008. This follow-up study published in 2008 found that for-profit hospice providers incur lower costs than non-profit providers and that some of these cost savings may be attributable to differences in staffing. However, differences in quality outcomes could not be identified, and the researchers called for future research examining “variation in [length-of-stay, nursing intensity, and provider skill mix] with patient clinical outcomes.” Id., at 1007.Google Scholar
See Kinzbrunner, , supra note 67, at 484.Google Scholar
Cherlin, E. J. et al., “Interdisciplinary Staffing Patterns: Do For-Profit and Nonprofit Hospices Differ?” Journal of Palliative Medicine 13, no. 4 (2010): 389–394, at 393.CrossRefGoogle Scholar
See Cherlin, et al., supra note 74, at 393. These findings are echoed by empirical data in “Economic Incentives in the Hospice Care Setting: A Comparison of For-Profit and Nonprofit Providers,” an unpublished manuscript by Noe, K. and Forgione, D. A. dated December 17, 2009 (on file with the authors).Google Scholar
See Wachterman, , supra note 54, at 478 (“… we are unable to assess the relationship between profit status and quality of care.”); Carlson, , Gallo, , and Bradley, , supra note 71, at 435; Foliart, D. E., Clausen, M., and Siljestrom, C., “Bereavement Practices among California Hospices: Results of a Statewide Survey,” Death Studies 25, no. 5 (2001): 461–67.Google Scholar
See Carlson, and Gallo, , & Bradley, , supra note 71, at 437.Google Scholar
von Gunten, C. F., “Profit or Not-for-Profit: Who Cares?” Journal of Palliative Medicine 11, no. 7 (2008): 954. Accord Gates, R. P., “Where Do We Go from Here?” American Journal of Hospice & Palliative Care 14, no. 2 (1997): 95 (“Many people thought, and still believe, that ‘for Profit’ hospice cannot remain true to the hospice visions. I believe those people have been proven wrong.”).10.1089/jpm.2008.9871CrossRefGoogle Scholar
See Cerminara, , supra note 66 (discussing provisions of The Patient Protection and Affordable Care Act that will require stricter monitoring processes designed to hold hospice providers more accountable, but which may also result in compliance burdens too great for small, rural hospice providers to satisfy).Google Scholar